Abion
Korea - SeoulBiotechnology
Focus: Abion is a Seoul-based biotech company founded in 2023, focused on small molecule oncology therapeutics. The company is publicly listed and operates as a pre-revenue stage biotech with a lean pipeline in early clinical development.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Abion?
AI assessmentHigh-risk, early-stage play best suited for mission-driven scientists seeking founding-team equity upside, not established professionals seeking stability.
Why Work Here
- Early-stage oncology biotech with public market access, offering potential equity upside if pipeline programs advance
- Focused pipeline in solid tumors with two Phase 2 programs (Vabametkib and ABN401) showing active clinical development
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
1 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Vabametkib
Advanced Solid TumorsClinical Trials (1)
NCT05541822To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Phase 2Help build intelligence for Abion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.